Cargando…
Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
PURPOSE: To characterize the incidence, risk factors and survival of patients with brain metastases at initial diagnosis of metastatic breast cancer (MBC) in China. METHODS: The China National Cancer Center database was used to identify 2087 MBC patients diagnosed between 2003 and 2015. Clinicopatho...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736978/ https://www.ncbi.nlm.nih.gov/pubmed/33310633 http://dx.doi.org/10.1016/j.breast.2020.11.021 |
_version_ | 1783622871824728064 |
---|---|
author | Li, Yiqun Li, Qiao Mo, Hongnan Guan, Xiuwen Lin, Shaoyan Wang, Zijing Chen, Yimeng Zhang, Ye Zhang, Dainan Chen, Shanshan Cai, Ruigang Wang, Jiayu Luo, Yang Fan, Ying Yuan, Peng Zhang, Pin Li, Qing Ma, Fei Xu, Binghe |
author_facet | Li, Yiqun Li, Qiao Mo, Hongnan Guan, Xiuwen Lin, Shaoyan Wang, Zijing Chen, Yimeng Zhang, Ye Zhang, Dainan Chen, Shanshan Cai, Ruigang Wang, Jiayu Luo, Yang Fan, Ying Yuan, Peng Zhang, Pin Li, Qing Ma, Fei Xu, Binghe |
author_sort | Li, Yiqun |
collection | PubMed |
description | PURPOSE: To characterize the incidence, risk factors and survival of patients with brain metastases at initial diagnosis of metastatic breast cancer (MBC) in China. METHODS: The China National Cancer Center database was used to identify 2087 MBC patients diagnosed between 2003 and 2015. Clinicopathological features, treatment and survival information were extracted. Multivariable logistic and Cox regression were performed to determine factors predictive of brain metastases at MBC diagnosis and survival, respectively. RESULTS: Brain metastases occurred in ninety patients (4.3%) at MBC diagnosis, and in 27 patients (2.5%), 42 patients (7.2%) and 21 patients (5.2%) with hormone receptor positive, human epidermal growth factor receptor 2 negative (HR + HER2-), HER2-positive and triple negative breast cancer (TNBC), respectively. HER2-positive subtype (OR = 2.38; 95% CI 1.40–4.04; p < 0.0001), TNBC subtype (OR = 1.89; 95% CI 1.02–3.51; p = 0.005), and metastases to all three sites of bone, liver and lungs (OR = 3.23; 95% CI 1.52–6.87; p = 0.002) were shown to increase the risk of BM at MBC diagnosis. Median survival after BM was 23.7 months. First-line tyrosine kinase inhibitors (TKI) improved survival compared to trastuzumab-based regimen (44.9 vs 35.4 months, p = 0.09). Factors that independently decreased BM death risk were ECOG<2, brain metastases only and multidisciplinary treatment. CONCLUSION: HER2-positive and TNBC subtypes have a higher incidence of BM at initial MBC diagnosis. Brain screening might be considered in patients with HER2-positive disease at MBC diagnosis, and further prospective randomized study is warranted. |
format | Online Article Text |
id | pubmed-7736978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-77369782020-12-18 Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China Li, Yiqun Li, Qiao Mo, Hongnan Guan, Xiuwen Lin, Shaoyan Wang, Zijing Chen, Yimeng Zhang, Ye Zhang, Dainan Chen, Shanshan Cai, Ruigang Wang, Jiayu Luo, Yang Fan, Ying Yuan, Peng Zhang, Pin Li, Qing Ma, Fei Xu, Binghe Breast Original Article PURPOSE: To characterize the incidence, risk factors and survival of patients with brain metastases at initial diagnosis of metastatic breast cancer (MBC) in China. METHODS: The China National Cancer Center database was used to identify 2087 MBC patients diagnosed between 2003 and 2015. Clinicopathological features, treatment and survival information were extracted. Multivariable logistic and Cox regression were performed to determine factors predictive of brain metastases at MBC diagnosis and survival, respectively. RESULTS: Brain metastases occurred in ninety patients (4.3%) at MBC diagnosis, and in 27 patients (2.5%), 42 patients (7.2%) and 21 patients (5.2%) with hormone receptor positive, human epidermal growth factor receptor 2 negative (HR + HER2-), HER2-positive and triple negative breast cancer (TNBC), respectively. HER2-positive subtype (OR = 2.38; 95% CI 1.40–4.04; p < 0.0001), TNBC subtype (OR = 1.89; 95% CI 1.02–3.51; p = 0.005), and metastases to all three sites of bone, liver and lungs (OR = 3.23; 95% CI 1.52–6.87; p = 0.002) were shown to increase the risk of BM at MBC diagnosis. Median survival after BM was 23.7 months. First-line tyrosine kinase inhibitors (TKI) improved survival compared to trastuzumab-based regimen (44.9 vs 35.4 months, p = 0.09). Factors that independently decreased BM death risk were ECOG<2, brain metastases only and multidisciplinary treatment. CONCLUSION: HER2-positive and TNBC subtypes have a higher incidence of BM at initial MBC diagnosis. Brain screening might be considered in patients with HER2-positive disease at MBC diagnosis, and further prospective randomized study is warranted. Elsevier 2020-12-04 /pmc/articles/PMC7736978/ /pubmed/33310633 http://dx.doi.org/10.1016/j.breast.2020.11.021 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Li, Yiqun Li, Qiao Mo, Hongnan Guan, Xiuwen Lin, Shaoyan Wang, Zijing Chen, Yimeng Zhang, Ye Zhang, Dainan Chen, Shanshan Cai, Ruigang Wang, Jiayu Luo, Yang Fan, Ying Yuan, Peng Zhang, Pin Li, Qing Ma, Fei Xu, Binghe Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China |
title | Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China |
title_full | Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China |
title_fullStr | Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China |
title_full_unstemmed | Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China |
title_short | Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China |
title_sort | incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in china |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736978/ https://www.ncbi.nlm.nih.gov/pubmed/33310633 http://dx.doi.org/10.1016/j.breast.2020.11.021 |
work_keys_str_mv | AT liyiqun incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT liqiao incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT mohongnan incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT guanxiuwen incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT linshaoyan incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT wangzijing incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT chenyimeng incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT zhangye incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT zhangdainan incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT chenshanshan incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT cairuigang incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT wangjiayu incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT luoyang incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT fanying incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT yuanpeng incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT zhangpin incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT liqing incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT mafei incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina AT xubinghe incidenceriskfactorsandsurvivalofpatientswithbrainmetastasesatinitialmetastaticbreastcancerdiagnosisinchina |